Lupin Limited sees double-digit Q3 growth

Lupin Limited has experienced a 19th successive quarter of growth during the three months ending on December 31st 2010.

The company has published its financial report for the third quarter of its 2010-11 fiscal year, revealing a net sales total of 14.67 billion rupees (201.59 million), up by 17 percent compared to Q3 2009-10.

Profit levels grew by 39 percent in the same timeframe, while its European business expanded by 72 percent, thanks to the successful introduction of products such as Trimetazidine and Clarithromycin XL.

Dr Kamal Sharma, managing director of Lupin Limited, said the company's sustained growth has been driven by a combination of good strategy and strong execution.

He added: "Our continued performance has been the result of a sustained endeavour from all our businesses to focus on ensuring growth."

Earlier this month, Lupin received clearance from healthcare regulators in the US to launch Nabumetone, a generic version of the GlaxoSmithKline osteoarthritis and rheumatoid arthritis treatment Relafen.